Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. (TSHA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · TSHA · as of Sep 30, 2025
Ownership Breakdown
159
Institutional Holders
▲ 7 vs Q2
$865.59M
Total Inst. Value
▲ $270.20M vs Q2
287.34M
Shares Outstanding
freeFloat 81.99%
264.62M
13F Shares Held
▲ 6.91M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
TSHA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RTW INVESTMENTS, LP biological products, (no diagnostic substances) | 24.35M | 8.17% | 8.17% | $79.64B | Nov 14, 2025 | ▼ 667.3K |
RA CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 23.56M | 7.90% | 7.90% | $77.03B | Nov 14, 2025 | — held |
AVORO CAPITAL ADVISORS LLC biological products, (no diagnostic substances) | 21.70M | 7.28% | 7.28% | $70.96B | Nov 14, 2025 | — held |
MORGAN STANLEY biological products, (no diagnostic substances) | 19.31M | 6.48% | 6.48% | $63.14B | May 27, 2026 | ▲ 2.44M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 16.36M | 5.49% | 5.49% | $53.51B | Nov 12, 2025 | ▲ 3.06M |
FMR LLC biological products, (no diagnostic substances) | 14.59M | 4.90% | 4.90% | $47.72B | Nov 13, 2025 | ▼ 1.03M |
GOLDMAN SACHS GROUP INC biological products, (no diagnostic substances) | 13.38M | 4.49% | 4.49% | $43.76B | Nov 14, 2025 | ▲ 796.0K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 12.85M | 4.31% | 4.31% | $42.02B | Nov 7, 2025 | ▲ 1.96M |
SIREN, L.L.C. biological products, (no diagnostic substances) | 11.01M | 3.70% | 3.70% | $36.02B | Nov 13, 2025 | — held |
OCTAGON CAPITAL ADVISORS LP biological products, (no diagnostic substances) | 9.07M | 3.04% | 3.04% | $29.65B | Nov 14, 2025 | ▼ 3.52M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
25
Increased
+29.84M shares2
New Positions
first time holders12
Decreased
−19.40M shares0
Sold Out
fully exitedNet shares change (top 50)
+10.44M
+29.84M / −19.40M
Net new holders
+15
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
TSHA insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
9
Buy transactions
2
Sell transactions
4.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Stalfort John A III director | Jun 1, 2026 | Award | 21,335 | — | — | 1.18M | Form 4 ↗ |
Stalfort John A III director | Jun 1, 2026 | Award | 42,671 | $5.97 | $254.7K | 42.7K | Form 4 ↗ |
Donenberg Phillip B. director | Jun 1, 2026 | Award | 21,335 | — | — | 241.3K | Form 4 ↗ |
Donenberg Phillip B. director | Jun 1, 2026 | Award | 42,671 | $5.97 | $254.7K | 42.7K | Form 4 ↗ |
Long Alison S director | Jun 1, 2026 | Award | 21,335 | — | — | 127.2K | Form 4 ↗ |
Long Alison S director | Jun 1, 2026 | Award | 42,671 | $5.97 | $254.7K | 42.7K | Form 4 ↗ |
Sepp-Lorenzino Laura director | Jun 1, 2026 | Award | 21,335 | — | — | 127.2K | Form 4 ↗ |
Sepp-Lorenzino Laura director | Jun 1, 2026 | Award | 42,671 | $5.97 | $254.7K | 42.7K | Form 4 ↗ |
Nagendran Sukumar President and Head of R&D | Apr 10, 2026 | Sale | 200,000 | $4.46 | $892.0K | 1.14M | Form 4 ↗ |
Alam Kamran CHIEF FINANCIAL OFFICER | Feb 4, 2026 | Sale | 1,655 | $4.52 | $7.5K | 1.44M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Taysha Gene Therapies, Inc. (TSHA) is primarily owned by institutional investors, who hold approximately 92.1% of total shares outstanding. Company insiders own approximately 18.01%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Taysha Gene Therapies, Inc. is RTW INVESTMENTS, LP, holding approximately 24.35 million shares — equal to 8.17% of outstanding shares — as of September 30, 2025.
A total of 159 institutional investors currently hold TSHA stock, with a combined institutional value of approximately $865,587,657 as of the most recent 13F filing period.
Frequently asked questions
TSHA ownershipTaysha Gene Therapies, Inc. (TSHA) is primarily owned by institutional investors, who hold approximately 92.1% of shares. The largest shareholder is RTW INVESTMENTS, LP with a 8.17% stake. Company insiders hold 18.01%. Data sourced from SEC Form 13F as of September 30, 2025.